Application of peptide geroprotectors in elderly patients
with age-related pathology
Prague Medical Report / Vol. 113 (2012) p 21-22
Authors: Khavinson V, Ryzhak GA, Mikhailova ON, Ryzhak AP
Institutions: IAGG-ER, St. Petersburg Institute of Bioregulation and Gerontology, Russia
A randomized, placebo-controlled clinical trial to study the effcacy of application of the brain and vessel peptide bioregulators in the complex treatment of DE was
conducted. 83 patients aged 62–75 and diagnosed with “DE stage I–II” partici-pated in the trial. The duration of the disease ranged from 2 months to 10 years.
The results of correction test showed that number of the browsed characters increased by 42% in patients of the second group and 48% in the third group
(19.2% in the control group). The use of Cerluten and Ventfort in complex treatment of DE improved the treatment efficacy 2.3 fold as compared to placebo-control. This justifes the em-ployment of brain and vessels geroprotectors in conventional treatment of DE stage I–II.
Authors: Khavinson V, Ryzhak GA, Mikhailova ON, Ryzhak AP
Institutions: IAGG-ER, St. Petersburg Institute of Bioregulation and Gerontology, Russia
A randomized, placebo-controlled clinical trial to study the effcacy of application of the brain and vessel peptide bioregulators in the complex treatment of DE was
conducted. 83 patients aged 62–75 and diagnosed with “DE stage I–II” partici-pated in the trial. The duration of the disease ranged from 2 months to 10 years.
The results of correction test showed that number of the browsed characters increased by 42% in patients of the second group and 48% in the third group
(19.2% in the control group). The use of Cerluten and Ventfort in complex treatment of DE improved the treatment efficacy 2.3 fold as compared to placebo-control. This justifes the em-ployment of brain and vessels geroprotectors in conventional treatment of DE stage I–II.
| application_of_peptide_geroprotectors_in_elderly_patients.pdf |
